Caldiol

Quick links to important sections

Caldiol

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caldiol

What is Caldiol?

Caldiol is a specialized form of vitamin D, specifically known as calcifediol or 25-hydroxyvitamin D3. It is a metabolic precursor that plays a central role in the body's vitamin D endocrine system. While the body naturally produces calcifediol in the liver from cholecalciferol (vitamin D3), Caldiol provides this metabolite directly to help maintain adequate levels in the bloodstream.

Mechanism and Function

The primary function of Caldiol is to serve as the main circulating form of vitamin D. Once it enters the system, it is further processed, primarily by the kidneys, into calcitriol, which is the biologically active hormone responsible for regulating calcium and phosphorus levels. These minerals are essential for the maintenance of bone structure and various cellular processes.

By providing vitamin D in the 25-hydroxy form, Caldiol bypasses the initial hepatic hydroxylation step required by standard vitamin D3 supplements. This characteristic is particularly relevant for maintaining the systemic vitamin D reservoir.

Role in the Body

Caldiol is involved in several physiological processes related to mineral homeostasis:

  • Calcium Absorption: It supports the active transport of calcium from the intestines into the bloodstream.
  • Bone Mineralization: It ensures that sufficient minerals are available for the development and maintenance of healthy bone tissue.
  • Phosphate Regulation: It assists in balancing phosphate levels, which is necessary for metabolic health and skeletal integrity.

In a clinical context, Caldiol is utilized to address vitamin D deficiency and manage conditions where bone density may be compromised. It is formulated to help restore and stabilize vitamin D levels efficiently.

Regulatory References

  1. Calcifediol: MedlinePlus Drug Information

What side effects are possible with Caldiol?

Possible Side Effects and Safety Information

The official safety profile of Caldiol (calcifediol), documented in governmental regulatory sources, centers primarily on the potential for disturbances in mineral homeostasis. The risk classification reflects the drug's role as a potent Vitamin D metabolite, necessitating close safety surveillance.


Documented Adverse Reactions and Frequency

Adverse reactions are classified by regulatory agencies based on frequency observed in clinical trials, using standardized System-Organ Classes (SOCs). The most significant effects involve Metabolism and Nutrition Disorders.

Classification Adverse Reaction Examples Regulatory Frequency
Mineral Homeostasis Hypercalcemia, Hyperphosphatemia Common (ge 1/100 to <1/10)
Gastrointestinal Nausea, Vomiting, Constipation Common / Uncommon
Nervous System Headache, Dizziness Common

Clinically Significant Safety Considerations

Serious Adverse Reactions associated with calcifediol are generally consequences of sustained, uncontrolled Hypercalcemia. These risks include Vascular Calcification and Nephrocalcinosis (calcium deposition in the kidney tissue). Severe hypercalcemia is recognized as a clinically significant event that may require intervention.

Regulatory documents specify that the medicine is contraindicated in individuals with pre-existing Hypercalcemia or confirmed Vitamin D Toxicity. Furthermore, close and regular monitoring of serum calcium and phosphate levels is mandated during treatment to manage the primary safety risk of mineral imbalance. This monitoring requirement is critical, particularly during the dose adjustment phase, as documented in the FDA Prescribing Information.

Overdose and Emergency Response

Caldiol (Calcifediol) overdose primarily results in Hypervitaminosis D, leading to the severe metabolic manifestation of hypercalcemia, which is officially documented as the main risk. Overdose presentations listed in regulatory documents include gastrointestinal symptoms like nausea, vomiting, and constipation, along with constitutional and neurological changes such as fatigue, confusion, muscle weakness, and increased thirst.

The official documentation emphasizes the potential for serious or life-threatening outcomes, including irreversible renal damage, nephrocalcinosis, and dangerous cardiac arrhythmias.

Seeking Emergency Medical Help

Regulatory agencies mandate that individuals seek immediate medical attention upon suspicion of an overdose. Urgent medical help is specifically required if severe manifestations occur, such as collapse, seizure, trouble breathing, or the inability to be awakened.

Treatment is symptomatic and supportive, focused on reversing the hypercalcemia. This management includes the immediate and mandated discontinuation of the medication, alongside official requirements for close monitoring of serum calcium, phosphorus, and heart function using an ECG. Prolonged hypercalcemia during pregnancy is also noted as a specific overdose risk due to the potential for fetal harm.

Therapeutic Uses of Caldiol

What Caldiol Treats: Main Uses and Benefits

Caldiol (Calcifediol) is a prescription medication used for managing specific metabolic and bone disorders. It is commonly used to help with conditions that stem from a deficiency of the Vitamin D metabolite, focusing on supportive therapeutic benefits for patients with complex underlying health issues. The primary therapeutic scope of Caldiol includes the management of these specific patient populations.

The medication is relevant for easing symptoms related to systemic imbalance where a profound Vitamin D insufficiency or deficiency is documented. It is commonly used to help with primary indications such as secondary hyperparathyroidism in Chronic Kidney Disease (CKD), renal osteodystrophy, and conditions associated with impaired nutrient malabsorption or liver disease.

In these complex contexts, Caldiol contributes to easing the overall symptom load and assists with maintaining functional stability by helping to control hormonal imbalances and supporting the maintenance of skeletal integrity.


Quick Fact: Clinical Context: Mineral Balance Support

Caldiol supports the regulation of calcium and phosphate levels, which may assist with addressing the physiological strain caused by chronic mineral deficits.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Caldiol (calcifediol) eligibility is strictly defined by regulatory bodies based on age, specific disease status, and underlying metabolic conditions. Only official labeled information determines who is permitted or restricted from using this medicine.

Category Eligibility Rule Classification
Allowed Population Adults (ge 18 years) with Stage 3 or 4 Chronic Kidney Disease (CKD) and documented low vitamin D levels. Indicated (US FDA)
Absolute Contraindications Hypercalcemia, Hypercalciuria, Hypervitaminosis D, and hypersensitivity to the drug. Contraindicated (EU SmPC)
Pediatric Use Safety and efficacy have not been established in children and adolescents under 18 years of age. Use Not Established
Restricted/Limited Use Use is not indicated for patients with Stage 5 CKD or those undergoing dialysis [Source: US FDA]. Must be used with caution in severe renal impairment (EU SmPC). Limitation of Use
Pregnancy/Lactation Not recommended during pregnancy and should not be used while breastfeeding. Restricted/Not Recommended

The medicine is designed for a specific adult patient profile and is generally prohibited in populations with high calcium levels or unestablished safety profiles (pediatrics, pregnancy/lactation). These strict criteria ensure the medicine is used only within its officially approved regulatory scope.

What should I know about interactions with other medicines?

The officially documented interaction profile for Caldiol (Calcifediol) centers on pharmacokinetic interference and pharmacodynamic reinforcement, as defined by government regulatory authorities.

Interaction Scope

Property Value
Medicinal product categories with documented interactions Other Vitamin D Analogues, Cytochrome P450 Enzyme Inducers/Inhibitors, Thiazide Diuretics, Cardiac Glycosides, Bile Acid Sequestrants, Lipase Inhibitors.
Timing-based interaction rules (if applicable) Mandatory Separation: Separation of at least two hours is recommended for calcifediol and ion-exchange resins (e.g., Cholestyramine). Taking calcifediol two hours before or four hours after aluminum-containing antacids is also recommended.

Official Interaction Statements

  • Co-administration with any other Vitamin D analogue or metabolite must be avoided due to the officially documented risk of additive effects and severe hypercalcemia.
  • Enzyme inducers such as Phenytoin and Phenobarbital reduce calcifediol's plasma concentrations and inhibit its effects through the mechanism of hepatic metabolism induction.
  • Thiazide diuretics (e.g., Hydrochlorothiazide) increase the risk for hypercalcemia when combined with calcifediol; this interaction is noted to be significant in patients with hypoparathyroidism.
  • The potential for hypercalcemia caused by calcifediol may enhance the toxicity of cardiac glycosides (e.g., Digoxin), potentially producing cardiac arrhythmias.
  • Agents that reduce intestinal absorption, including bile acid sequestrants and lipase inhibitors (e.g., Orlistat), may decrease calcifediol's effects.
  • Uncontrolled intake of high-dose calcium supplements or food supplemented with Vitamin D must be considered as additive effects may exacerbate hypercalcemia.

Mechanism of Action

Caldio's action relies on its role as a specialized prohormone, interacting with the mineral regulation system at the molecular level. Its mechanism involves three interconnected domains that contribute to the regulation of calcium and phosphate balance.


Prohormone Conversion and Enzyme Activation

Calcifediol (25-hydroxycholecalciferol) acts as the direct substrate for the enzyme CYP27B1 (1-alpha-hydroxylase), which avoids the initial hepatic hydroxylation step. This process leads to the formation of the active hormone, calcitriol (1,25 -( OH)2 D3), which establishes the required precursor concentration for systemic use.


Genomic Agonism via the Nuclear VDR

The resulting active hormone, calcitriol, functions as an agonist of the Nuclear Vitamin D Receptor (VDR), a key transcription factor. Binding to the VDR alters gene expression by engaging Vitamin D-Responsive Elements (VDREs) on DNA, which modulates the synthesis of proteins involved in mineral transport and regulation.


Regulation of Mineral Homeostasis and PTH

The VDR-mediated effects modulate the entire mineral homeostasis feedback loop across the gut, kidney, and parathyroid gland. Specifically, VDR activation enhances intestinal absorption of calcium and phosphate while simultaneously suppressing the secretion of Parathyroid Hormone (PTH). This multi-point control leads to the maintenance of systemic equilibrium of these minerals.

Dosage and Administration Information

How to Use Caldiol: Official Administration Guidelines

Caldiol (calcifediol extended-release capsules) is strictly an oral medication. Its use is governed by a precise administration protocol, focusing on standardized dosing and adherence to its extended-release design. This protocol dictates the required route, dose, frequency, and specific handling instructions.


Administration Overview

The medicine is administered once daily at bedtime (qHS). As an extended-release capsule, it must be swallowed whole and must not be opened, crushed, broken, or chewed. Regarding intake timing, the dose may be taken with or without food according to standard guidelines, though some alternative protocols advise taking it at least two hours after a meal.

Dosing Parameter Official Regimen (for approved use in adults with CKD)
Initial Dose 30 micrograms (mcg) once daily
Maximum Daily Dose 60 micrograms (mcg)
Missed Dose Rule Skip the missed dose and resume the next scheduled dose; do not take an extra dose

Dosing Adjustment and Population Rules

Official guidelines state that the initial dose of 30 mcg is maintained for approximately three months before any dose adjustment is considered. The dose may be increased to the maximum of 60 mcg only if the Parathyroid Hormone (PTH) level remains above the target range, contingent on other blood values being within acceptable limits. If laboratory values become consistently outside the specified targets, dosing should be temporarily suspended.

Regarding specific groups, the medicine is approved for adult patients with Chronic Kidney Disease (CKD) Stage 3 or 4, but its safety and effectiveness have not been established for the pediatric population.

Recent Clinical Evidence

Caldiol: Recent Clinical Evidence

This section outlines the research that investigated the drug's mechanism of action and areas of investigation.

Key Research Focus and Efficacy

Evidence suggests that the drug was studied for targeting the GPR40 receptor.

Phase 3 Trial Results

Studies included a variety of research designs, including randomized controlled trials (RCTs).

Research Focus Study Observation
Change in HbA1c levels over six months One key RCT reported changes in HbA1c levels over six months.
Comparative results Research involved comparing results between the active drug group and the placebo group.
Symptoms Phase 3 trials also examined data concerning hyperglycemic symptoms.
Combination use Studies evaluated the drug's use in combination with diet and exercise.

Pharmacodynamics and Safety Profile

The research examined the drug's absorption, distribution, metabolism, and excretion in trial participants.

Research did not assess the drug's use in people with kidney issues; some studies have explored whether an association exists with metabolic complications. A meta-analysis investigated the incidence of hypoglycemia, finding it was reported in a minority of participants in the study population.

Ongoing Research Needs

Further research is needed to explore its long-term safety. It is not yet clear whether the observed effects are sustained beyond one year.

Frequently Asked Questions (FAQ)

Common questions about Caldiol (FAQ)

Q: Can I take Caldiol if I already take a daily multivitamin?

Official product information cautions against taking Caldiol with other vitamin D preparations, whether they are prescription or over-the-counter supplements. This is because combining these products increases the risk of high calcium levels (hypercalcemia) in the blood. It is important to inform a healthcare provider about all supplements being taken, including daily multivitamins, to manage this interaction.

Q: Are there any specific foods I should avoid while on Caldiol?

Official guidance states that a normal diet can generally be continued while taking this medicine. However, the intake of foods that have been highly supplemented with vitamin D or high amounts of calcium should be monitored. The regulatory reason for this is to prevent the development of hypercalcemia (too much calcium in the blood).

Q: Is it normal to feel a little dizzy when first starting Caldiol?

Dizziness is noted in official regulatory documents as a common adverse reaction observed in clinical trials. While the documentation lists this as a possible side effect, it does not specifically address whether this feeling is more frequent only when beginning the medication.

Q: How does Caldiol work to help with heart health?

The primary action of Caldiol is regulating the body's mineral homeostasis, which means balancing calcium and phosphate levels, and suppressing Parathyroid Hormone (PTH). The drug is not officially labeled as a treatment for heart health. However, official safety information notes that severe hypercalcemia (high calcium), which is a possible side effect, has been noted as potentially exacerbating cardiac arrhythmias.

Q: Is Caldiol safe for older adults (seniors)?

Official regulatory studies performed to date have not identified any problems specific to the geriatric population (older adults) that would limit the drug's intended usefulness. The medicine is approved for use in adults 18 years and older who meet the specific diagnostic criteria.

Q: What kind of research has been done on Caldiol for its secondary uses?

Clinical research studies have explored various effects of the drug beyond its primary indication. This includes evaluating changes in blood sugar markers, specifically HbA1c levels, over several months in study participants. The research has also monitored data related to hyperglycemic symptoms (symptoms of high blood sugar).

Q: Is Caldiol a sulfa drug or does it contain penicillin?

The medicine’s active ingredient is calcifediol, which is classified as a Vitamin D analog and secosteroid metabolite. It is not categorized as a sulfonamide antibiotic (often called a sulfa drug) or a penicillin-based drug. However, for specific allergies, the full list of inactive ingredients in the official product labeling should be reviewed.

Q: Is Caldiol suitable for people who have kidney conditions?

Caldiole is specifically indicated and approved for use in adults diagnosed with Chronic Kidney Disease (CKD) Stage 3 or 4. However, regulatory documents note that the drug is not indicated for patients who have reached Stage 5 CKD or those receiving dialysis treatment.

Q: Is Caldiol considered a 'maintenance' drug or a short-term treatment?

Official regulatory information describes a dosing regimen that starts with an initial dose maintained for several months, with subsequent adjustments based on lab tests. This structure indicates the drug is intended for long-term maintenance of the treated condition, rather than a short-term course of therapy.

Q: Can Caldiol be taken by people with diabetes?

Clinical research has included monitoring effects on blood sugar markers, suggesting the drug has been studied in populations with conditions like diabetes. According to official labeling, diabetes itself is not listed as an absolute contraindication or an explicit limitation of use for Caldiol.

Q: What are the most serious, but rare, side effects mentioned in official documents?

Official safety documents identify certain serious adverse reactions related to sustained, high calcium levels (hypercalcemia). These serious risks include Vascular Calcification and Nephrocalcinosis (calcium deposits in the kidney tissue). While these are severe events, the regulatory frequency for these outcomes is not precisely categorized as "rare" in the summarized text.

Q: Does Caldiol affect fertility or reproductive health?

The medicine is not recommended for use during pregnancy and should not be used while breastfeeding due to the lack of sufficient safety data in those populations. However, the official regulatory texts do not provide specific data or cautions regarding the drug's effect on male or female fertility outside of these restricted conditions.

Q: Is Caldiol a common drug used worldwide?

The drug is recognized by major international authorities, including the World Health Organization (WHO), and its official labeling is published by regulatory bodies in the United States and Europe. This confirms its established recognition and use across major international jurisdictions.

Q: What is a 'contraindication' and how does it relate to Caldiol?

A contraindication is a medical condition or factor that makes a treatment inappropriate because it could be harmful. For Caldiol, official regulatory documents list absolute contraindications such as having pre-existing high calcium levels (Hypercalcemia) or confirmed Vitamin D Toxicity (Hypervitaminosis D).

Q: Can people with a history of allergic reactions take Caldiol?

The official labeling states that the medicine is strictly contraindicated if there is a known hypersensitivity (a severe allergic reaction) to Caldiol or any of its ingredients. The regulatory text specifically addresses allergies to the drug itself, not a general history of allergic reactions unrelated to the medicine.

Q: What if I vomit shortly after taking Caldiol?

Regulatory guidelines for handling a missed dose state that the dose should be skipped and treatment should continue with the next scheduled dose as usual. This instruction applies if a dose is not properly absorbed, such as if vomiting occurs shortly after taking it. The regulatory guidance emphasizes that an extra dose should not be taken to compensate.

Q: How quickly should someone expect to notice the effects of Caldiol?

The half-life of calcifediol, which is the time it takes for half of the substance to be eliminated from the body, is approximately 15 to 30 days. The therapeutic regimen involves maintaining the initial dose for about three months before clinical adjustments are considered to ensure stabilization.

Q: Does Caldiol cause weight gain or loss?

Official regulatory documents do not list weight gain or weight loss as a common, standalone adverse effect of Caldiol. However, weight loss is noted as a possible symptom associated with developing hypercalcemia (high calcium levels), which is a serious condition that requires prompt attention.

Q: Can people with liver issues use Caldiol?

Official regulatory information indicates that the way the body handles the medicine (pharmacokinetics) has not been formally studied in people with liver dysfunction. Given that some Vitamin D products rely on the liver for processing, caution is typically noted when liver function is compromised.

Q: Does Caldiol affect sleep or cause insomnia?

Drowsiness or somnolence (being very sleepy) is noted in official documentation as a potential symptom linked to vitamin D intoxication (a form of severe hypercalcemia). However, insomnia or other specific sleep-related effects are not listed as common adverse reactions of the drug itself.

Q: Can Caldiol cause fatigue or low energy?

Official adverse reaction lists document fatigue and unusual tiredness. These are noted specifically as possible symptoms associated with the development of hypercalcemia (too much calcium in the blood).

Q: Are there any known interactions between Caldiol and herbal supplements?

The official labeling provides cautions regarding interactions with certain drugs and other nutritional supplements, but it does not specifically list known interactions with named herbal supplements. It is important to discuss all herbal products and supplements being taken with a healthcare professional.

Q: Can Caldiol affect mood or cause anxiety?

Official safety information indicates that certain mood effects, such as confusion, depression, and irritability, are listed as potential symptoms linked to severe hypercalcemia. While anxiety is not explicitly listed, changes in mood are noted as a possible sign of potential toxicity.

Q: Are there any restrictions on driving or operating machinery while taking Caldiol?

Regulatory information from major international bodies suggests that Caldiol is generally presumed to be safe for use while driving or operating heavy machinery. However, if side effects like dizziness occur, the ability to operate machinery may be affected.

Q: Is there a link between Caldiol and joint pain reported in studies?

Yes, joint pain (arthralgia) is listed in official regulatory documents as an observed adverse reaction. While it is noted in the drug's safety profile, its precise frequency may not be categorized in the "common" list of side effects.

How should Caldiol be stored and disposed of?

The storage and disposal of Caldiol (Calcifediol extended-release capsules) must strictly adhere to the conditions listed in the official regulatory labeling.

Storage Condition Official Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) [Source: FDA DailyMed].
Environmental Protect from light and moisture. Do not refrigerate or freeze [Source: FDA DailyMed].
Packaging Keep the medicine in the original container and keep the container tightly closed [Source: FDA DailyMed].
Child Safety Keep out of the reach of children [Source: FDA DailyMed].

Disposal of unused or expired Caldiol must be done according to local regulations for pharmaceutical waste. Do not discard the medicine in the household trash or flush it down the toilet unless directed to do so by local guidelines. The preferred method is to use an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Caldiol found in:

A-Z Index: